Changing the name of polycystic ovary syndrome to metabolic syndrome
In a landmark medical move aimed at correcting misconceptions and expanding access to women's healthcare, the global medical community has agreed to a radical renaming of polycystic ovary syndrome (PCOS ) to "polycystic ovary syndrome" (PCOS) by May 2026. This significant change comes as part of a broad international consensus published in the prestigious medical journal The Lancet, with the participation of 56 professional and health organizations worldwide. This decision aims to move beyond the medical reduction of the condition to mere ovarian cysts and to acknowledge its complex hormonal and metabolic roots.
Historical roots and evolution in understanding polycystic ovary syndrome
Historically, this condition was first discovered and described in the 1930s, when medical attention focused primarily on outward symptoms such as infertility and ovarian cysts. For decades, millions of women worldwide suffered from inaccurate or delayed diagnoses due to this limited understanding. As medical research advanced, it became clear that the old name did not fully reflect the scientific reality of the disease, necessitating a more comprehensive term that encompasses the hormonal and metabolic imbalance affecting various body systems, not just the reproductive system.
Accurate scientific understanding and metabolic dimensions
In this context, Dr. Reem Mohammed Moussa Al-Amoudi, a consultant in endocrinology and metabolic diseases at King Abdulaziz Medical City of the National Guard in Jeddah, confirmed that the new name reflects a more accurate scientific understanding of the condition. She explained that the syndrome is linked to underlying disorders such as insulin resistance, which increases the risk of developing type 2 diabetes and cardiovascular disease. Dr. Al-Amoudi indicated that the new name corrects a common misconception and contributes to promoting a comprehensive treatment approach for patients, noting that this approach will focus primarily on improving lifestyle, enhancing metabolic health, and long-term prevention of complications.
Expected impact on polycystic ovary syndrome treatment protocols
For his part, Dr. Firas Al-Kharouf, a consultant in obstetrics, gynecology, and maternal medicine, described this change as a pivotal shift in understanding the disease. He anticipated that the new terminology would positively impact treatment protocols both locally and internationally by expanding the scope of medical assessment to include routine screening for cardiovascular and metabolic risks. Dr. Al-Kharouf added that clinics would see a greater tendency to rely on insulin-resistant medications alongside traditional treatments, emphasizing that a comprehensive understanding of the condition would contribute to early diagnosis and reduce future complications that could threaten the patient's life.
Updating international guidelines and the transition phase
In a related context, Dr. Yazid Al-Yousef, a consultant in obstetrics, gynecology, and laparoscopic surgery, revealed that the current diagnostic criteria will remain in place without immediate change. He explained that the global medical system will enter a three-year transition period extending until the international guidelines are updated in 2028. He noted that both names will be used together in medical records and international classifications during this period to ensure a smooth transition.
Addressing insulin resistance and ending the stigma
Dr. Al-Yousef anticipated that this landmark decision would contribute to increased awareness among physicians across all specialties, thereby reducing the current 70% delay in diagnosis. He emphasized that traditional treatments would remain essential, but the new terminology promotes a shift towards addressing insulin resistance, the primary driver of the disease. He concluded by affirming that the change aims to eliminate the misinformation and social stigma associated with the disease, empowering patients to manage their health long-term with enhanced research and medical support.
